Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say

Core Insights - Moderna reported a revenue of $1.02 billion for the quarter ended September 2025, which is a decrease of 45.4% compared to the same period last year [1] - The earnings per share (EPS) was -$0.51, a decline from $0.03 in the year-ago quarter, but it exceeded the consensus EPS estimate of -$2.15 by 76.28% [1] - The revenue surpassed the Zacks Consensus Estimate of $860.07 million by 18.13% [1] Revenue Breakdown - Product sales in the Rest of the World were $175 million, falling short of the estimated $196.36 million, representing a 46% decline year-over-year [4] - Product sales in the United States reached $782 million, exceeding the average estimate of $499.39 million, but still reflecting a 35.6% decrease from the previous year [4] - Net product sales totaled $973 million, surpassing the estimated $835.12 million, marking a 46.5% decline year-over-year [4] - Other revenue amounted to $43 million, exceeding the average estimate of $25.19 million, showing a year-over-year increase of 2.4% [4] - Grant revenue within other revenue was $14 million, significantly higher than the estimated $5.56 million, indicating a 100% increase compared to the year-ago quarter [4] Stock Performance - Over the past month, Moderna's shares have declined by 15.6%, while the Zacks S&P 500 composite increased by 1.3% [3] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]